CLINOMICS INC. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1,799 KRW | -2.02% |
|
-3.80% | -29.86% |
| Sales 2022 | 23.08B 16.76M 1.4B | Sales 2023 | 11.41B 8.28M 691M | Capitalization | 82.01B 59.54M 4.97B |
|---|---|---|---|---|---|
| Net income 2022 | -10.18B -7.39M -617M | Net income 2023 | -42.26B -30.68M -2.56B | EV / Sales 2022 | 3.93 x |
| Net Debt 2022 | 2.54B 1.85M 154M | Net Debt 2023 | 6.94B 5.03M 420M | EV / Sales 2023 | 7.8 x |
| P/E ratio 2022 |
-8.62
x | P/E ratio 2023 |
-1.63
x | Employees | 71 |
| Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 83.92% |
More Fundamentals
* Assessed data
More news
| 1 day | -2.02% | ||
| 1 week | -3.80% | ||
| Current month | +7.27% | ||
| 1 month | +10.03% | ||
| 3 months | -21.78% | ||
| 6 months | -13.92% | ||
| Current year | -29.86% |
1 week
1 792.00
2 090.00
1 month
1 677.002 090.00
Current year
1 335.003 080.00
1 year
1 335.006 466.67
3 years
1 335.0012 500.00
5 years
1 335.0017 433.33
10 years
1 335.0017 433.33
| Managers | Title | Age | Since |
|---|---|---|---|
Jong-Tae Jung
CEO | Chief Executive Officer | 62 | 24/21/24 |
Byung-Chul Kim
CEO | Chief Executive Officer | 59 | 21/11/21 |
Sung-Hun Lee
CTO | Chief Tech/Sci/R&D Officer | 47 | 01/20/01 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Byung-Chul Kim
CEO | Chief Executive Officer | 59 | 21/11/21 |
Jong-Hwa Park
BRD | Director/Board Member | 56 | 01/18/01 |
Jong-Tae Jung
CEO | Chief Executive Officer | 62 | 24/21/24 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/24/26 | 1,799 | -2.02% | 130,177 |
| 25/24/25 | 1,836 | -4.47% | 456,703 |
| 24/24/24 | 1,922 | -3.90% | 608,317 |
| 23/24/23 | 2,000 | +5.37% | 1,038,257 |
| 22/24/22 | 1,898 | +1.50% | 285,348 |
End-of-day quote Korea S.E., April 26, 2024
More quotes
Clinomics Inc is a Korea-based company engaged in the development of genome diagnostic tests and liquid biopsies. The Company's main businesses are multi-omics-based service business and liquid biopsy-based cancer diagnosis and screening business. The multi-omics-based service business provides products and services that predict physical characteristics and diseases based on genome diagnosis and tests, and provides early diagnosis services for major diseases such as cancer based on multi-omics. The liquid biopsy-based cancer diagnosis and screening business sells medical devices that diagnose patients by extracting blood cells and deoxyribonucleic acid (DNA), and diagnostic and monitoring kits for cancer mutations in patients. It is also develops products that diagnoses cancer early with blood.
Calendar
13/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| -29.86% | 42.88M | |
| +1.51% | 42.75B | |
| +48.26% | 41.61B | |
| +8.57% | 41.34B | |
| -12.36% | 26.59B | |
| +8.92% | 25.49B | |
| -25.13% | 18.12B | |
| +29.17% | 12.24B | |
| -3.12% | 11.76B | |
| +6.35% | 11B |
- Stock Market
- Equities
- A352770 Stock
